Bristol-Myers Squibb Co.
NYSE:BMY 2:56:10 PM EDT
Products, Regulatory
U.S. Food And Drug Administration Approves Opdivo® (Nivolumab) For The Adjuvant Treatment Of Patients With High-Risk Urothelial Carcinoma
Published: 08/20/2021 16:06 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients With High-risk Urothelial Carcinoma.
Bristol-myers Squibb - in Checkmate -274, Opdivo Nearly Doubled Median Disease-free Survival Compared to Placebo in Intent-to-treat Population.
Bristol-myers Squibb Co - Results Support Conversion of Opdivo's Accelerated Approval to a Regular Approval in This Setting.
Bristol-myers Squibb - in Checkmate -274, Opdivo Nearly Doubled Median Disease-free Survival Compared to Placebo in Intent-to-treat Population.
Bristol-myers Squibb Co - Results Support Conversion of Opdivo's Accelerated Approval to a Regular Approval in This Setting.